✦ LIBER ✦

363 Dose of the molecularly targeted agents (MTA) in Phase 1 trials correlates with clinical benefit

✍ Scribed by S. Gupta; A. Alqwasmi; S. Hunsberger; L. Rubinstein; P. Ivy; R. Royds; P. LoRusso

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Heterogeneity in the definition of dose-

✍ Christophe Le Tourneau; Albiruni R.A. Razak; Hui K. Gan; Simona Pop; Véronique D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 159 KB

1232 POSTER Creatinine Clearance (CrCI)

✍ J. Vitfell-Pedersen; B. Basu; V. Moreno; A. Tjokrowidjaja; M. Puglisi; K. Shah; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

1260 POSTER Preliminary Signs of Efficac

✍ J. Arrondeau; X. Paoletti; S. Pop; P. Tresca; V. Dieras; C. Le Tourneau 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 61 KB

449 Increased levels of serum creatine k

✍ V. Moreno Garcia; R. Molife; J. Pedersen; M. Puglisi; M. Blanco; B. Basu; K. Sha 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

RE: Meta-analysis of the Relationship Be

✍ Jain, R. K.; Lee, J. J.; Hong, D.; Kurzrock, R. 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 110 KB

Dose Escalation to Target Volumes of Hel

✍ Xia, T.; Chang, D.; Wang, Y.; Li, J.; Wu, W.; Zhu, F. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB